Sign In
Last checked at 
29 Jun 2021 12:05
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
Director Dealing
Cambridge, UK, 29th June 2021. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that Susan Lowther, Chief Financial Officer, has purchased 12,515 ordinary shares of £0.01 each in the capital of the Company ("Ordinary Shares") at a price of 235 pence per Ordinary Share.
Following the transaction, the total beneficial interest of Susan Lowther is 110,681 Ordinary Shares, representing 0.40% of the total voting rights.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc | www.arecor.com |
Dr Sarah Howell, Chief Executive Officer | Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
|
Susan Lowther, Chief Financial Officer | Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
|
Mo Noonan, Communications | Tel: +44 (0) 7876 444977 Email: mo.noonan@arecor.com |
|
|
Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) | Tel: +44 (0) 20 7886 2500
|
|
|
Consilium Strategic Communications |
|
Chris Gardner, David Daley, Angela Gray | Tel: +44 (0) 20 3709 5700 Email: arecor@consilium-comms.com |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.
For further details please see our website, www.arecor.com
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Susan Lowther |
2 | Reason for the notification | |
a) | Position/status | Chief Financial Officer |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Arecor Therapeutics plc |
b) | LEI | 98450093D12I3A8DDD58 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument | Ordinary Shares |
b) | Identification Code | GB00BMWLM973 |
c) | Nature of the transaction | Purchase of shares |
d) | Price(s) and volume(s) | 235 pence and 12,515 Ordinary Shares |
e) | Aggregated information - Aggregated volume - Aggregated price | N/A |
f) | Date of the transaction | 29 June 2021 |
g) | Place of the transaction | London Stock Exchange, AIM |
Follow the stocks
